Talquetamab - multiple myeloma after at least three prior lines of therapy
Bull Cancer. 2024 Mar 7:S0007-4551(24)00049-3. doi: 10.1016/j.bulcan.2023.12.014. Online ahead of print.NO ABSTRACTPMID:38458925 | DOI:10.1016/j.bulcan.2023.12.014 (Source: Bulletin du Cancer)
Source: Bulletin du Cancer - March 8, 2024 Category: Cancer & Oncology Authors: Thomas Fatrara Emilie Chalayer Source Type: research
Sacituzumab-govitecan in hormone-receptor positive/HER2-negative advanced breast cancer
Bull Cancer. 2024 Mar 7:S0007-4551(24)00046-8. doi: 10.1016/j.bulcan.2023.12.011. Online ahead of print.NO ABSTRACTPMID:38458926 | DOI:10.1016/j.bulcan.2023.12.011 (Source: Bulletin du Cancer)
Source: Bulletin du Cancer - March 8, 2024 Category: Cancer & Oncology Authors: Hanna Besnainou Luc Cabel Source Type: research
PAL-PRAT study: Healthcare workers' knowledge and perception of palliative practices in a Cancer Center
DISCUSSION: This survey underlines the importance of training and support for the professionals caring for patients in palliative situation and their relatives in France.PMID:38458927 | DOI:10.1016/j.bulcan.2023.12.009 (Source: Bulletin du Cancer)
Source: Bulletin du Cancer - March 8, 2024 Category: Cancer & Oncology Authors: Marie Locatelli C écile Flahault Nicolas Roche Christine Mateus Fran çois Blot None Lucile Montalescot Jean-Bernard Le Provost L éonor Fasse Source Type: research
Barriers and facilitators to physical activity in oncology in Seine-Saint-Denis: A qualitative study using the socio-ecological approach
DISCUSSION: A diversity of representations, combinations of factors, and experiences are described. Getting people with cancer to engage in and maintain long-term physical activity is a complex task, requiring multidisciplinary action on all socio-ecological factors.PMID:38458928 | DOI:10.1016/j.bulcan.2023.12.017 (Source: Bulletin du Cancer)
Source: Bulletin du Cancer - March 8, 2024 Category: Cancer & Oncology Authors: C édric Sarreboubee Albane Aumaitre Lazhar Labiadh Aude-Marie Foucaut Source Type: research
Pembrolizumab+chemotherapy as first-line treatment in patients with HER negative advanced oesogastric adenocarcinoma
Bull Cancer. 2024 Mar 7:S0007-4551(24)00072-9. doi: 10.1016/j.bulcan.2024.01.004. Online ahead of print.NO ABSTRACTPMID:38458924 | DOI:10.1016/j.bulcan.2024.01.004 (Source: Bulletin du Cancer)
Source: Bulletin du Cancer - March 8, 2024 Category: Cancer & Oncology Authors: Martin Duval Aziz Zaanan Source Type: research
Talquetamab - multiple myeloma after at least three prior lines of therapy
Bull Cancer. 2024 Mar 7:S0007-4551(24)00049-3. doi: 10.1016/j.bulcan.2023.12.014. Online ahead of print.NO ABSTRACTPMID:38458925 | DOI:10.1016/j.bulcan.2023.12.014 (Source: Bulletin du Cancer)
Source: Bulletin du Cancer - March 8, 2024 Category: Cancer & Oncology Authors: Thomas Fatrara Emilie Chalayer Source Type: research
Sacituzumab-govitecan in hormone-receptor positive/HER2-negative advanced breast cancer
Bull Cancer. 2024 Mar 7:S0007-4551(24)00046-8. doi: 10.1016/j.bulcan.2023.12.011. Online ahead of print.NO ABSTRACTPMID:38458926 | DOI:10.1016/j.bulcan.2023.12.011 (Source: Bulletin du Cancer)
Source: Bulletin du Cancer - March 8, 2024 Category: Cancer & Oncology Authors: Hanna Besnainou Luc Cabel Source Type: research
PAL-PRAT study: Healthcare workers' knowledge and perception of palliative practices in a Cancer Center
DISCUSSION: This survey underlines the importance of training and support for the professionals caring for patients in palliative situation and their relatives in France.PMID:38458927 | DOI:10.1016/j.bulcan.2023.12.009 (Source: Bulletin du Cancer)
Source: Bulletin du Cancer - March 8, 2024 Category: Cancer & Oncology Authors: Marie Locatelli C écile Flahault Nicolas Roche Christine Mateus Fran çois Blot None Lucile Montalescot Jean-Bernard Le Provost L éonor Fasse Source Type: research
Barriers and facilitators to physical activity in oncology in Seine-Saint-Denis: A qualitative study using the socio-ecological approach
DISCUSSION: A diversity of representations, combinations of factors, and experiences are described. Getting people with cancer to engage in and maintain long-term physical activity is a complex task, requiring multidisciplinary action on all socio-ecological factors.PMID:38458928 | DOI:10.1016/j.bulcan.2023.12.017 (Source: Bulletin du Cancer)
Source: Bulletin du Cancer - March 8, 2024 Category: Cancer & Oncology Authors: C édric Sarreboubee Albane Aumaitre Lazhar Labiadh Aude-Marie Foucaut Source Type: research
Effects of extended aromatase inhibitors in women with hormone-dependent breast cancer who have already received five years of adjuvant hormone therapy: A systematic review and meta-analysis
DISCUSSION: Prolonged AI therapy has significant benefits in terms of disease-free survival in women with hormone-dependent breast cancer. However, adverse effects and a lack of evidence for a benefit on overall survival must be considered in the decision-making process regarding adjuvant hormone therapy extension.PMID:38453587 | DOI:10.1016/j.bulcan.2023.12.016 (Source: Bulletin du Cancer)
Source: Bulletin du Cancer - March 7, 2024 Category: Cancer & Oncology Authors: Kossi Cl ément Trenou Miceline M ésidor Caroline Diorio Aida Eslami Denis Talbot Source Type: research
Effects of extended aromatase inhibitors in women with hormone-dependent breast cancer who have already received five years of adjuvant hormone therapy: A systematic review and meta-analysis
DISCUSSION: Prolonged AI therapy has significant benefits in terms of disease-free survival in women with hormone-dependent breast cancer. However, adverse effects and a lack of evidence for a benefit on overall survival must be considered in the decision-making process regarding adjuvant hormone therapy extension.PMID:38453587 | DOI:10.1016/j.bulcan.2023.12.016 (Source: Bulletin du Cancer)
Source: Bulletin du Cancer - March 7, 2024 Category: Cancer & Oncology Authors: Kossi Cl ément Trenou Miceline M ésidor Caroline Diorio Aida Eslami Denis Talbot Source Type: research
Interest of focal radiotherapy in case of oligoprogression under immunotherapy in the treatment of metastatic non-small cell lung cancer
CONCLUSION: The combination of focal radiotherapy in case of oligoprogression and continued treatment with nivolumab in the treatment of metastatic NSCLC in the second or subsequent line of treatment seems to be with an increase in PFS.PMID:38445648 | DOI:10.1016/j.bulcan.2023.09.006 (Source: Bulletin du Cancer)
Source: Bulletin du Cancer - March 6, 2024 Category: Cancer & Oncology Authors: Ana ïs Gagé Bruno Pereira Aur élie Belliere Henri Janicot Ga ëlle Jeannin Clara Bourrachot Muriel Durand Camille Rolland-Debord Patrick Merle Source Type: research
Interest of focal radiotherapy in case of oligoprogression under immunotherapy in the treatment of metastatic non-small cell lung cancer
CONCLUSION: The combination of focal radiotherapy in case of oligoprogression and continued treatment with nivolumab in the treatment of metastatic NSCLC in the second or subsequent line of treatment seems to be with an increase in PFS.PMID:38445648 | DOI:10.1016/j.bulcan.2023.09.006 (Source: Bulletin du Cancer)
Source: Bulletin du Cancer - March 6, 2024 Category: Cancer & Oncology Authors: Ana ïs Gagé Bruno Pereira Aur élie Belliere Henri Janicot Ga ëlle Jeannin Clara Bourrachot Muriel Durand Camille Rolland-Debord Patrick Merle Source Type: research
Implementation of pharmaceutical consultations in digestive oncology in a teaching hospital: 1-year outcomes
DISCUSSION: This activity enables us to review with patients essential aspects of their care, such as implanting an implantable chamber catheter, anti-cancer treatment and managing potential side effects and improve their self-care skills.PMID:38438283 | DOI:10.1016/j.bulcan.2024.01.003 (Source: Bulletin du Cancer)
Source: Bulletin du Cancer - March 4, 2024 Category: Cancer & Oncology Authors: Pierre Chapron Mathilde Petit Jean-Fran çois Huon Pierre Nizet Source Type: research
The circulating PD-L1: An emerging predictive biomarker for immune checkpoint inhibitors response
Bull Cancer. 2024 Mar 3:S0007-4551(24)00048-1. doi: 10.1016/j.bulcan.2023.12.013. Online ahead of print.ABSTRACTImmune checkpoint inhibitors (ICI) have recently become the standard of care for many metastatic solid tumors, with considerable improvements in patient prognosis. However, a non-negligible proportion of patients does not respond to this type of treatment, making it essential to identify predictive factors of this response in order to better adapt the therapy. Among the biomarkers that have been most extensively studied in recent years, tumor PD-L1 levels come out on top, with controversial results for predicting...
Source: Bulletin du Cancer - March 4, 2024 Category: Cancer & Oncology Authors: Fanny Chovet Anne-Sophie Passot Quentin Mangon Paul Rouzaire Aurore Doug é Source Type: research
